• View patient site
  • Order
Oncimmune
  • Our Company
    • About Oncimmune
    • Board of Directors
    • Scientific Board
    • Regulation & Quality
    • Press Releases
    • Events & News
  • Products
    • Lung Cancer Blood Test
    • Liver Cancer Blood Test
  • Resources
    • Industry Publications
    • Oncimmune Resources
    • Videos
  • Investors
    • Corporate Governance
    • Regulatory Newsflow
    • Share Price and Tools
    • Shareholder Analysis
    • Analyst Coverage
    • Results, Reports & Presentations
    • Corporate Documents
    • Investor & Advisor Contacts
    • Aim Rule 26
  • Contact Us
  • Our Company
    • About Oncimmune
    • Board of Directors
    • Scientific Board
    • Regulation & Quality
    • Press Releases
    • Events & News
  • Products
    • Lung Cancer Blood Test
    • Liver Cancer Blood Test
  • Resources
    • Industry Publications
    • Oncimmune Resources
    • Videos
  • Investors
    • Corporate Governance
    • Regulatory Newsflow
    • Share Price and Tools
    • Shareholder Analysis
    • Analyst Coverage
    • Results, Reports & Presentations
    • Corporate Documents
    • Investor & Advisor Contacts
    • Aim Rule 26
  • Contact Us

Early Cancer Detection Insights

October 01, 2018

Potential utility of a Positive EarlyCDT®—Lung Blood Biomarker Test in Indeterminate Pulmonary Nodules.

Read More
September 30, 2018

Development and validation of an ELISA test detecting a panel of autoantibodies in combination with AFP for early detection of hepatocellular carcinoma

Read More
November 01, 2017

Determination of the detection lead time for autoantibody biomarkers in early stage lung cancer using the UKCTOCS cohort

Read More
October 13, 2017

Changes in Smoking Behaviour in the Early Cancer Detection Test Lung Cancer Scotland (ECLS) Study

Read More
October 12, 2017

Is Lung Cancer Screening Associated with a Negative Psychological Impact?

Read More
October 03, 2017

How Does Screening for the Early Detection of Lung Cancer Facilitate Smoking Cessation? A Qualitative Study of Screened Smokers

Read More
September 12, 2017

Autoantibodies as additive biomarkers to AFP for the detection of HCC

Read More
May 01, 2017

Tumor-Associated Autoantibodies: Re-Optimization of EarlyCDT®—Lung Diagnostic Performance and Its Application to Indeterminate Pulmonary Nodules

Read More
March 27, 2017

Autoantibody Signature Enhances the Positive Predictive Power of Computed Tomography for Detection of Lung Cancer

Read More
oncimmune
brand

Oncimmune Holdings Plc
Clinical Sciences Building,
Nottingham City Hospital
Hucknall Road, Nottingham,
NG5 1PB, United Kingdom
+44 (0)115 82 31869

 

Registered in England and Wales number 09818395

Oncimmune (USA) LLC
8960 Commerce Drive,
Building #6,
De Soto,
KS 66018, USA
1 913 583 9000
1 888 583 9030

Terms & Conditions Privacy Policy Cookies
twitter facebook linkedin